What are the outcomes of omalizumab therapy in the treatment of asthma?

Updated: Jan 07, 2019
  • Author: Michael J Morris, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Therapy has been shown to decrease free IgE antibody levels by 99% and cell receptor sites for IgE antibody by 97%. This decrease, in turn, is associated with reduced histamine production (90%), early-phase bronchospasm (40%), and late-phase bronchospasm (70%), as well as a decrease in the number, migration, and activity of eosinophils. Levels drop quickly and remain low for at least a month. This therapy is also effective for allergic rhinitis.

Multiple phase 3 trials show that compared to placebo injections, treatment is associated with larger median inhaled steroid dose reduction (83% vs 50%), higher percentage of discontinuation of inhaled steroids (42% vs 19%), and fewer asthma exacerbations (approximately 15% vs 30%). Quality of life and use of rescue inhaler and the emergency department may also be improved. Omalizumab has been shown to reduce the number of asthma exacerbations.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!